FDA Grants Orphan Drug Designation to Pegrizeprument for Heart Transplant Rejection Prevention
Key Insights
Veloxis Pharmaceuticals (search)' pegrizeprument (search) (VEL-101) received FDA Orphan Drug Designation for preventing heart allograft rejection in transplant patients.
The pegylated monoclonal antibody fragment blocks CD28 (search)-mediated T cell activation while preserving CTLA-4 (search) immunosuppressive functions through a dual mechanism.
This designation follows a previous orphan status for liver transplant rejection prevention, addressing unmet needs in solid organ transplantation.
Veloxis Pharmaceuticals (search) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to pegrizeprument (search) (VEL-101) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant. This regulatory milestone follows the recent orphan designation for liver transplant rejection prevention and represents a significant advancement in addressing unmet needs within the transplant community.
Novel Mechanism Targets T Cell Costimulation
Pegrizeprument (search) is a pegylated monoclonal antibody fragment that employs a dual mechanism of action to prevent organ rejection. The drug binds to and blocks CD28 (search)-mediated effector-T cell costimulation while preserving CTLA-4 (search) function, an important protein that naturally regulates immune responses. This selective approach allows pegrizeprument to directly block CD28-mediated T cell activation while indirectly maintaining CTLA-4 mediated immunosuppressive functions.
"We are encouraged by the FDA's decision to grant Orphan Drug Designation for heart transplant patients, which underscores the need for innovative therapies in this population," said Stacy Wheeler, CEO of Veloxis. "This designation for pegrizeprument (search) further demonstrates our commitment to developing groundbreaking therapeutics that improve patient outcomes and quality of life for solid organ transplant recipients."
Addressing Critical Gaps in Post-Transplant Care
While orthotopic heart transplantation serves as a life-saving procedure for patients with heart failure, recipients require lifelong immunosuppression that often involves complex dosing regimens and comorbid toxicities. Despite advancements in post-transplant clinical care, complications from immunosuppression and allograft rejection continue to negatively impact both graft and patient survival.
The orphan designation reinforces Veloxis' commitment to advancing pegrizeprument (search) as a targeted therapy that may address these critical gaps in long-term post-transplant care. The FDA Orphan Drug Designation program grants special status to investigational drugs and biologics targeting rare diseases and medical conditions affecting fewer than 200,000 people in the United States.
Development and Licensing Background
Pegrizeprument (search), also known as VEL-101 and FR104, was licensed by Veloxis Pharmaceuticals (search) from OSE Immunotherapeutics in April 2021. The licensing agreement granted Veloxis worldwide rights to develop, manufacture, and commercialize pegrizeprument for all transplant indications. The drug is currently being developed for the prevention of acute rejection in solid organ transplant recipients.
Veloxis Pharmaceuticals (search), a subsidiary of Asahi Kasei Corporation (search), operates as a global specialty pharmaceutical company focused on improving the lives of transplant patients. The company, headquartered in Cary, North Carolina, specializes in the development and commercialization of medications for transplant patients and those with serious related diseases.